-
Something wrong with this record ?
Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response
Z. Strizova, M. Kuchar, L. Capkova, M. Komarc, J. Skrivan, J. Bartunkova, J. Plzak, D. Smrz
Language English Country Switzerland
Document type Journal Article
Grant support
364218
Grantová Agentura, Univerzita Karlova
PRIMUS/MED/12
Univerzita Karlova v Praze
Progres Q28 [First Faculty of Medicine]
Univerzita Karlova v Praze
AZV 16-28135A
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Directory of Open Access Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
Salivary gland carcinomas (SGCs) are extremely morphologically heterogeneous, and treatment options for this disease are limited. Immunotherapy with immune checkpoint inhibitors (ICIs) represents a revolutionary treatment approach. However, SGCs remain largely resistant to this therapy. An increasing body of evidence suggests that resistance to ICI therapy is modulated by the Fas (CD95)-Fas ligand (FasL, CD178) interplay between tumor cells and immune cells. In this study, we examined the Fas-FasL interplay between tumor cells and tumor-infiltrating immune cells (TIICs) in the center and periphery of SGCs from 62 patients. We found that the Fas-expressing tumor cells accumulated in the center of SGC tumors with increasing tumor stage. Furthermore, this accumulation occurred regardless of the presence of TIICs expressing high levels of FasL. On the contrary, a loss of Fas-expressing TIICs with increasing tumor stage was found in the tumor periphery, whereas FasL expression in tumor cells in the tumor periphery correlated with tumor stage. These data suggest that SGC cells are resistant to FasL-induced apoptosis by TIICs but could utilize FasL to eliminate these cells in high-stage tumors to provide resistance to immunotherapy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018004
- 003
- CZ-PrNML
- 005
- 20210729104108.0
- 007
- ta
- 008
- 210726s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biomedicines9040402 $2 doi
- 035 __
- $a (PubMed)33917866
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Strizova, Zuzana $u Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University, 15006 Prague, Czech Republic
- 245 10
- $a Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response / $c Z. Strizova, M. Kuchar, L. Capkova, M. Komarc, J. Skrivan, J. Bartunkova, J. Plzak, D. Smrz
- 520 9_
- $a Salivary gland carcinomas (SGCs) are extremely morphologically heterogeneous, and treatment options for this disease are limited. Immunotherapy with immune checkpoint inhibitors (ICIs) represents a revolutionary treatment approach. However, SGCs remain largely resistant to this therapy. An increasing body of evidence suggests that resistance to ICI therapy is modulated by the Fas (CD95)-Fas ligand (FasL, CD178) interplay between tumor cells and immune cells. In this study, we examined the Fas-FasL interplay between tumor cells and tumor-infiltrating immune cells (TIICs) in the center and periphery of SGCs from 62 patients. We found that the Fas-expressing tumor cells accumulated in the center of SGC tumors with increasing tumor stage. Furthermore, this accumulation occurred regardless of the presence of TIICs expressing high levels of FasL. On the contrary, a loss of Fas-expressing TIICs with increasing tumor stage was found in the tumor periphery, whereas FasL expression in tumor cells in the tumor periphery correlated with tumor stage. These data suggest that SGC cells are resistant to FasL-induced apoptosis by TIICs but could utilize FasL to eliminate these cells in high-stage tumors to provide resistance to immunotherapy.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kuchar, Martin $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, University Hospital Motol, Charles University, 15006 Prague, Czech Republic
- 700 1_
- $a Capkova, Linda $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University, 15006 Prague, Czech Republic
- 700 1_
- $a Komarc, Martin $u Department of Methodology, Faculty of Physical Education and Sport, Charles University, 15006 Prague, Czech Republic
- 700 1_
- $a Skrivan, Jiri $u Department of Otorhinolaryngology, Second Faculty of Medicine, University Hospital Motol, Charles University, 15006 Prague, Czech Republic
- 700 1_
- $a Bartunkova, Jirina $u Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University, 15006 Prague, Czech Republic
- 700 1_
- $a Plzak, Jan $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, University Hospital Motol, Charles University, 15006 Prague, Czech Republic
- 700 1_
- $a Smrz, Daniel $u Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University, 15006 Prague, Czech Republic
- 773 0_
- $w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 9, č. 4 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33917866 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104107 $b ABA008
- 999 __
- $a ind $b bmc $g 1676495 $s 1138446
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 9 $c 4 $e 20210408 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
- GRA __
- $a 364218 $p Grantová Agentura, Univerzita Karlova
- GRA __
- $a PRIMUS/MED/12 $p Univerzita Karlova v Praze
- GRA __
- $a Progres Q28 [First Faculty of Medicine] $p Univerzita Karlova v Praze
- GRA __
- $a AZV 16-28135A $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20210726
